Pneumoconiosis future or investigational therapies
|
Pneumoconiosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pneumoconiosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Pneumoconiosis future or investigational therapies |
|
Pneumoconiosis future or investigational therapies in the news |
|
Risk calculators and risk factors for Pneumoconiosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Future or Investigational Therapies
Future therapies are being experimented on including inhibiting cytokines and the use of antioxidants. Investigational therapy also includes administration of bone marrow-derived mononuclear cells. [1] [2] [3]
References
- ↑ Rimal B, Greenberg AK, Rom WN (2005). "Basic pathogenetic mechanisms in silicosis: current understanding". Curr Opin Pulm Med. 11 (2): 169–73. doi:10.1097/01.mcp.0000152998.11335.24. PMID 15699791.
- ↑ Maron-Gutierrez T, Castiglione RC, Xisto DG, Oliveira MG, Cruz FF, Peçanha R; et al. (2011). "Bone marrow-derived mononuclear cell therapy attenuates silica-induced lung fibrosis". Eur Respir J. 37 (5): 1217–25. doi:10.1183/09031936.00205009. PMID 20693250.
- ↑ Cavalli G, Fallanca F, Dinarello CA, Dagna L (2015). "Treating pulmonary silicosis by blocking interleukin 1". Am J Respir Crit Care Med. 191 (5): 596–8. doi:10.1164/rccm.201412-2150LE. PMID 25723826.